Transparency notifications BlackRock, Inc.

Brussels (Belgium), 1 August 2019 – 20:00 (CEST) – regulated information

1.  Summary of the notifications

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received 3 transparency notifications from BlackRock, Inc. (having its registered office at 55 East 52nd Street, New York, NY, 10055, U.S.A.), dated 26, 29 and 30 July 2019 respectively.

In the first notification, BlackRock, Inc., has notified that, following a disposal of UCB shares with voting rights and a disposal of equivalent financial instruments by its affiliates, its total holding in UCB SA/NV has decreased and has crossed downwards the 5% threshold on 25 July 2019.

On 25 July 2019, BlackRock, Inc. (taking into account the holding of its affiliates) Inc. owned 9 215 306 UCB shares with voting rights (versus 9 320 710 shares in its previous notification), representing 4.74% of the total number of shares issued by the company (194 505 658) (versus 4.79% in its previous notification), as well as 431 570 equivalent financial instruments (versus 433 129 in its previous notification) representing 0.22% of the total number of shares issued by the company (same % as in its previous notification).

In the second notification, BlackRock, Inc., has notified that, following an acquisition of UCB shares with voting rights and a disposal of equivalent financial instruments by its affiliates, its total holding in UCB SA/NV has increased and has crossed the 5% threshold on 26 July 2019.

On 26 July 2019, BlackRock, Inc. (taking into account the holding of its affiliates) 9 617 448 UCB shares with voting rights, representing 4.94% of the total number of shares issued by the company, as well as 180 549 equivalent financial instruments, representing 0.09% of the total number of shares issued by the company.

In the third notification, BlackRock, Inc., has notified that, following a disposal of UCB shares with voting rights and an acquisition of equivalent financial instruments by its affiliates, its total holding in UCB SA/NV has decreased and has crossed downwards the 5% threshold on 29 July 2019.

On 29 July 2019, BlackRock, Inc. (taking into account the holding of its affiliates) 9 438 644 UCB shares with voting rights, representing 4.85% of the total number of shares issued by the company, as well as 186 998 equivalent financial instruments, representing 0.10% of the total number of shares issued by the company.

2.  Further information

This press release and the detailed transparency notifications are available on UCB SA/NV’s website via the following link.

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV’s website via the following link.

Investor Relations

Antje Witte, Investor Relations, UCB
T +32 2 559 94 14,
antje.witte@ucb.com

Isabelle Ghellynck, Investor Relations, UCB
T +32 2 559 95 88,
isabelle.ghellynck@ucb.com

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.6 billion in 2018. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news